Can Intercept Make it to the Finishing Line in NASH?
Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) is a biopharmaceutical Company aiming to create novel therapeutics for the treatment of progressive non-viral liver diseases. The Company’s lead compound Ocalive or obeticholic acid (OCA), is an analog of the bile acid chenodeoxycholic acid (CDCA), which is being evaluated for...
